Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 1991 Jun;74(6):905-9
Date
06/01/1991Pubmed ID
2033450DOI
10.3171/jns.1991.74.6.0905Scopus ID
2-s2.0-0025736863 (requires institutional sign-in at Scopus site) 96 CitationsAbstract
In a randomized postoperative trial, adjuvant post-irradiation chemotherapy, consisting of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP), was tested versus radiation therapy alone for newly diagnosed medulloblastoma in patients between 1 and 21 years of age. Patients treated with irradiation plus MOPP had a statistically significant increase in overall survival rate at 5 years posttreatment compared to patients treated with radiation therapy alone (74% vs. 56%; p = 0.06, adjusted for race and gender). Although the overall study failed to show a statistically significant advantage for irradiation plus MOPP in event-free survival (p = 0.18), statistical significance was attained in children 5 years of age or older (p = 0.05). More severe hematological toxicities occurred in the group with irradiation plus MOPP; however, this hematotoxicity appeared to be tolerable and acceptable. These results suggest that patients may benefit from combined irradiation and chemotherapy following surgery for medulloblastoma.
Author List
Krischer JP, Ragab AH, Kun L, Kim TH, Laurent JP, Boyett JM, Cornell CJ, Link M, Luthy AR, Camitta BMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Age Factors
Antineoplastic Combined Chemotherapy Protocols
Cerebellar Neoplasms
Child
Child, Preschool
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Infant
Male
Mechlorethamine
Medulloblastoma
Prednisone
Procarbazine
Sex Factors
Survival Rate
Vincristine
